Geron (GERN) 10-Q2014 Q1 Quarterly report

Filed: 1 May 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abdominal, abroad, abuse, acid, added, administer, administered, affinity, allegedly, altogether, assert, attention, attorney, background, baseline, bone, brand, branded, breakdown, burden, cGMP, chemotherapy, chronic, cited, Code, concept, convenient, danazol, deacetylase, deducting, discomfort, dismissal, dissemination, divert, document, enacted, exert, expansion, factual, false, fashion, feedback, fiduciary, FLT, formal, fraud, gap, grow, growth, heading, heat, hedgehog, hemorrhage, hepatotoxicity, hindered, histone, hold, holder, hydroxyurea, hypomethylating, imaging, immaterial, impeding, implicit, IND, indefinitely, ineffective, ingredient, interdependent, interferon, intracranial, intrusion, investee, irradiation, itching, Jakafi, justify, kinase, lenalidomide, LFT, lift, lifted, lifting, light, long, marrow, Mateo, Medicaid, minimally, Minnesota, misappropriated, misleading, MM, momelotinib, monetary, mTOR, myelosuppression, night, noncurrent, nonmonetary, nucleic, outpatient, owner, pacritinib, pathway, payable, payor, pegylated, pentraxin, permission, persistent, pharmacoeconomic, plaintiff, post, President, proliferation, proof, proportionate, protein, purported, purporting, randomized, recombinant, recover, refractory, release, relief, responded, ringed, Rochester, ruxolitinib, safer, satiety, sensitive, sequestration, shift, shock, Similarly, splenectomy, splenic, splenomegaly, statute, stockholder, stopped, subpopulation, substance, suffer, surrendered, survival, taxable, thalidomide, threat, timeline, tyrosine, unauthorized, uncontrolled, underwritten, undetermined, unspecified, variable, withholding, worldwide

Removed: abnormal, accelerated, activation, advanced, Affordability, agriculture, Asia, assay, assignment, August, biosimilar, Biotech, Carlo, cohort, comprised, confirmation, consolidated, constitutionality, contractor, creating, currency, dose, dosing, elimination, endpoint, excise, exclusivity, expanded, expanding, factor, federally, fourth, functional, funded, GE, half, iii, illustrate, imposing, increasing, independence, innovative, Kingdom, landscape, lattice, leading, losing, lung, modification, Monte, monthly, negotiate, nonrefundable, North, NSCLC, nutritional, outplacement, oversight, PPACA, projected, proportion, propose, range, reach, reduction, refine, remission, removed, replication, resultant, satisfied, secondary, Secretary, simulation, substituted, supportive, susceptible, termination, thereunder, tolerability, transferred, transfusion, translated, translation, upheld, valid, validate, ViaCyte, voluntary, wind, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

GERN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Geron Corporation (the “Company”) hereby certifies, to such officer’s knowledge, that:

(i) the accompanying quarterly report on Form 10-Q of the Company for the quarter ended March 31, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 1, 2014	/s/ JOHN A. SCARLETT
	JOHN A. SCARLETT, M.D.
	President and Chief Executive Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.